Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov ID: NCT01336738

Public ClinicalTrials.gov record NCT01336738. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Week, Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-04991532 And Sitagliptin In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin

Study identification

NCT ID
NCT01336738
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
266 participants

Conditions and interventions

Interventions

  • 150 mg PF-04991532 Drug
  • 450 mg PF-04991532 Drug
  • 750 mg PF-04991532 Drug
  • Placebo Drug
  • Sitagliptin 100 mg Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2011
Primary completion
Feb 29, 2012
Completion
Feb 29, 2012
Last update posted
Aug 5, 2013

2011 – 2012

United States locations

U.S. sites
28
U.S. states
16
U.S. cities
24
Facility City State ZIP Site status
Pfizer Investigational Site Jonesboro Arkansas 72401
Pfizer Investigational Site Jonesboro Arkansas 72404
Pfizer Investigational Site Los Angeles California 90057
Pfizer Investigational Site Palm Springs California 92262
Pfizer Investigational Site Jacksonville Florida 32216
Pfizer Investigational Site Melbourne Florida 32901
Pfizer Investigational Site West Palm Beach Florida 33401
Pfizer Investigational Site Conyers Georgia 30094
Pfizer Investigational Site Chicago Illinois 60607
Pfizer Investigational Site Louisville Kentucky 40213
Pfizer Investigational Site Fall River Massachusetts 02720
Pfizer Investigational Site Brooklyn New York 11230
Pfizer Investigational Site Cary North Carolina 27518
Pfizer Investigational Site Wilmington North Carolina 28401
Pfizer Investigational Site Columbus Ohio 43213
Pfizer Investigational Site East Providence Rhode Island 02914
Pfizer Investigational Site East Providence Rhode Island 02915
Pfizer Investigational Site Mt. Pleasant South Carolina 29464
Pfizer Investigational Site Bristol Tennessee 37620
Pfizer Investigational Site Kingsport Tennessee 37660
Pfizer Investigational Site Dallas Texas 75230
Pfizer Investigational Site Houston Texas 77036
Pfizer Investigational Site Houston Texas 77074
Pfizer Investigational Site Houston Texas 77081
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Charlottesville Virginia 22911
Pfizer Investigational Site Kenosha Wisconsin 53142
Pfizer Investigational Site Milwaukee Wisconsin 53209

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01336738, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 5, 2013 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01336738 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →